Soft-Tissue Augmentation During Implant Placement in the Aesthetic Zone: Clinical, Radiographic, Histological and Patient-Reported Outcomes From a Randomised Controlled Trial Using Connective Tissue Graft and a Volume-Stable Collagen Matrix.

CBCT assessment of marginal bone loss and pink esthetic outcomes following peri-implant soft tissue augmentation with fascia lata allograft, platelet-rich fibrin, and connective tissue graft: a randomized controlled trial

CTG provided the most favorable combined esthetic and radiographic outcome, and PRF improved esthetic integration but was associated with greater early marginal bone loss and should be considered an adjunct rather than a full replacement for volume-stable grafting.

Comparison of conventional and micro-surgical techniques for gingival recession using collagen matrix: Randomised controlled split-mouth clinical trial.

Clinical outcomes of free gingival graft, xenogeneic collagen matrix, and acellular dermal matrix for peri-implant keratinized mucosa augmentation: a randomized controlled trial

Comparative efficacy of fascia lata allograft, platelet-rich fibrin, and connective tissue graft for peri-implant soft tissue augmentation: a randomized controlled clinical trial

Adequate peri-implant soft tissue thickness and keratinized mucosa width are crucial for implant health and aesthetics. Autogenous subepithelial connective tissue grafts (CTG) are the gold-standard for augmenting thin biotypes, but they require a second surgical site. This trial evaluated whether a human fascia lata allograft (FLA) or platelet-rich fibrin (PRF) membrane could comparably enhance peri-implant soft tissue phenotype and serve as less invasive alternatives of CTG. Forty-five patients with a thin gingival phenotype (≤ 1 mm thickness) requiring upper anterior implant were randomly assigned to receive soft tissue augmentation with either (1) FLA allograft, (2) PRF membrane, or (3) CTG (control). Interventions were applied concurrently with implant placement in a standardized manner. Gingival thickness (GT) and keratinized tissue width (KTW) were measured at baseline and 6 months using transgingival probing and clinical indices. Labial bone thickness was assessed by cone-beam CT at implant placement and 6 months. Forty-five enrolled patients completed the study. All treatment modalities showed improvements in gingival and bone parameters, with the connective tissue graft consistently demonstrating the greatest gains. The median keratinized tissue width increased to 4.00 mm in the Connective Tissue Graft group, slightly higher than the Fascial Lata Allograft and Platelet-Rich Fibrin groups (3.75 mm). Gingival thickness showed significant increases in all groups, with the Connective Tissue Graft reaching 2.15 mm, followed by Fascia Lata Allograft (1.80 mm) and Platelet-Rich Fibrin (1.55 mm). Labial bone thickness also increased, with the Connective Tissue Graft achieving the highest mean value of 2.300 mm, and after 6 months, significant gains were observed in both this group (p = 0.032) and in the Platelet-Rich Fibrin group (p = 0.044), while Fascia Lata Allograft showed a smaller, non-significant increase. Both fascia lata allograft (FLA) and PRF improved peri-implant soft tissue parameters, however the connective tissue graft (CTG) remains the gold standard for achieving the greatest thickness and best aesthetic results. FLA is a promising alternative that avoids a second surgical site with comparable outcomes, whereas PRF offers faster healing but lacks the volume necessary for significant tissue modification.

Assessment of Narrow-Diameter Implants Placed in the Posterior Region for Rehabilitation with a Single Crown: A Retrospective Cross-Sectional Clinical Study.

NDIs in the posterior regions rehabilitated with a single-unit crown are a reasonable, reliable, and feasible option for oral rehabilitation.

A comparative evaluation of implant stability and crestal bone loss in T-PRF-treated and conventional implants: A split-mouth clinical study

Introduction: This study aimed to compare implant stability and crestal bone loss between titanium platelet-rich fibrin (T-PRF)-treated implants and conventional implants. Methods: A prospective, randomized, split-mouth clinical trial was conducted in 10 healthy patients, with 20 implants per mouth (test and control). Each patient received one T-PRF-treated implant and one conventional implant. Implant stability was assessed using implant stability quotient (ISQ) at placement and at 3 months. Crestal bone loss was evaluated radiographically at 3 and 6 months. Soft tissue parameters were assessed at follow-up visits. Results: The T-PRF group showed higher ISQ values and reduced bone loss, with trends favoring the intervention at the three-month follow-up compared with the control group. Bone loss at three and six months was lower around anterior implants in the T-PRF group than in the control group. At this time, T-PRF may help improve soft tissue measurements; however, the measured values did not differ significantly from those of the control groups. Due to limitations such as a small sample size, a relatively short follow-up period, and varying baseline crestal bone levels, these findings should be interpreted with caution. Conclusion: Due to the restrictions of this split-mouth study, T-PRF-treated sites showed a trend towards increased early implant stability and decreased crestal bone loss compared to control sites. However, because of the small sample size and short follow-up period, conclusive evidence cannot be drawn about the clinical superiority of T-PRF. Further appropriately powered randomized controlled trials with prolonged follow-up periods are necessary to determine the long-term clinical efficacy of T-PRF in implant therapy. Clinical Trial Registration number: CTRI/2022/11/047159.